PSC
ALXN

Piper Sandler & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Piper Sandler & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,500
Closed -$1.13M – 127
2015
Q1 		$1.13M Buy
+6,500
New +$1.18M 0.47% 20
2014
Q2 		– Sell
-100
Closed -$15K – 154
2014
Q1 		$15K Buy
+100
New +$15.9K 0.01% 92

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Piper Sandler & Co's ALXN Position: Q2 2015 in Review

Piper Sandler & Co sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 6,500 shares — an estimated $1.13M sold.

Piper Sandler & Co first reported a position in ALXN in Q1 2014 and held it in 2 quarters. The position peaked at $1.13M in Q1 2015. 547 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

  • Piper Sandler & Co reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 6,500 Alexion Pharmaceuticals shares in Q2 2015, an estimated $1.13M.
  • Piper Sandler & Co first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Piper Sandler & Co's Alexion Pharmaceuticals position peaked at $1.13M in Q1 2015.
  • 547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Piper Sandler & Co's 13F filing for Q2 2015, filed 14 Aug 2015.